<!doctype html>
<html lang="es">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<title>Spanish Daily – Dec 23, 2025</title>
<meta name="color-scheme" content="light" />
<style>
  :root { --maxw: 800px; color-scheme: light; }
  html { -webkit-text-size-adjust: 100%; }
  body {
    margin: 0;
    padding: 0;
    background-color: #ffffff;
    color: #111111;
    font-family: system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial,sans-serif,Apple Color Emoji,Segoe UI Emoji;
    line-height: 1.6;
    font-size: 18px;
  }
  header, main, footer { max-width: var(--maxw); margin: 0 auto; padding: 16px; }
  header { padding-top: 20px; }
  h1 { font-size: 1.4rem; margin: 0 0 8px; }
  .subtle { opacity: 0.72; font-size: 0.95rem; }
  .card { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 14px; margin: 12px 0; }
  .tip-word { all: unset; display: inline; position: relative; cursor: pointer;
    text-decoration: underline dotted; text-underline-offset: 3px;
    padding: 0 .1em; border-radius: .35em; background: rgba(255,235,59,.28); }
  .tooltip { position: fixed; padding: .48rem .6rem; background: rgba(0,0,0,.88); color: #fff;
    border-radius: .55rem; font-size: .95rem; line-height: 1.3; max-width: min(90vw, 26rem);
    z-index: 9999; box-shadow: 0 6px 18px rgba(0,0,0,.18); }
  .content { white-space: pre-line; }
  .card { margin-bottom: 1.5em; line-height: 1.6; }
  strong { display: inline-block; margin-top: .35em; }
  details { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 12px; }
  details + details, details + .card { margin-top: 12px; }
  summary { cursor: pointer; font-weight: 600; }
  summary::marker { content: ""; }
  summary::after { content: " ▸"; }
  details[open] summary::after { content: " ▾"; }
  .debug { position: fixed; bottom: 8px; right: 8px; font-size: 12px; opacity: .6; }
</style>
</head>
<body>
  <header>
    <h1>Spanish Daily</h1>
    <div class="subtle">Toca una palabra subrayada para ver la traducción. Toca fuera para cerrar.</div>
  </header>

  <main>
    <!-- Spanish first -->
    <section class="card content">
STORY

La <span title="diabetes">diabetes</span> y la <span title="obesity">obesidad</span> <span title="are key components">son componentes clave</span> de la <span title="cardiometabolic disease">enfermedad cardiometabólica</span> (CKM). Las <span title="new guidelines">nuevas guías</span> de la ADA <span title="indicate that care should focus less">indican que la atención debe enfocarse menos</span> en la <span title="glucose">glucosa</span> y más en la <span title="organ protection and weight">protección de órganos y el peso</span>.

<span title="Use GLP-1 receptor agonists or tirzepatide">Use agonistas del receptor GLP-1 o tirzepatida</span> en la <span title="majority of patients">mayoría de los pacientes</span> con <span title="type 2 diabetes and obesity">diabetes tipo 2 y obesidad</span> <span title="when weight loss and CKM risk reduction">cuando la pérdida de peso y la reducción del riesgo CKM</span> <span title="are the main goals">sean los principales objetivos</span>. <span title="This is valid even if">Esto es válido incluso si</span> la <span title="baseline HbA1c">HbA1c basal</span> <span title="is not high">no es alta</span>, <span title="when there are cardiorenal indications">cuando existen indicaciones cardiorrenales</span> (por ejemplo, semaglutida STEP; tirzepatida SURMOUNT y SURPASS).

En <span title="patients with established atherosclerotic cardiovascular disease">pacientes con enfermedad cardiovascular aterosclerótica (ASCVD) establecida</span> o <span title="high risk">alto riesgo</span>, <span title="choose a GLP-1 receptor agonist">elija un agonista del receptor GLP-1</span> <span title="with proven reduction of major cardiovascular events">con reducción comprobada de eventos cardiovasculares mayores</span> (MACE) (por ejemplo, semaglutida, dulaglutida). La <span title="tirzepatide improves weight and metabolic risk factors">tirzepatida mejora el peso y los factores de riesgo metabólicos</span>, pero <span title="cardiovascular outcomes data for MACE">los datos de resultados cardiovasculares para MACE</span> <span title="are not yet definitive">aún no son definitivos</span>.

En <span title="heart failure">insuficiencia cardíaca</span> (especialmente <span title="HF with preserved ejection fraction">IC con fracción de eyección preservada</span>, HFpEF) o <span title="chronic kidney disease">enfermedad renal crónica</span> (ERC) (<span title="GFR">TFG</span> ≥20–25 mL/min/1.73 m², <span title="depending on the drug">según el fármaco</span>), <span title="start an SGLT2 inhibitor">inicie un inhibidor de SGLT2</span> <span title="with outcomes data">con datos de resultados</span> (empagliflozina, dapagliflozina, canagliflozina) <span title="early on">de forma temprana</span>, <span title="with any HbA1c">con cualquier HbA1c</span>, <span title="according to EMPA-REG, DAPA-HF, EMPEROR, CREDENCE and DAPA-CKD">según EMPA-REG, DAPA-HF, EMPEROR, CREDENCE y DAPA-CKD</span>.

En <span title="patients with obesity and CKD or heart failure">pacientes con obesidad y ERC o insuficiencia cardíaca</span>, <span title="use GLP-1RA or tirzepatide plus an SGLT2 inhibitor together if possible">use GLP-1RA o tirzepatida más un iSGLT2 juntos si es posible</span>. El <span title="early use for weight, heart failure, kidney and ASCVD risk">uso temprano para peso, insuficiencia cardíaca, riñón y riesgo de ASCVD</span> <span title="is more important than the order">es más importante que el orden</span>.

La <span title="metformin remains appropriate as first medication">metformina sigue siendo adecuada como primer medicamento</span>. Pero <span title="do not wait to start">no espere para iniciar</span> GLP-1RA, tirzepatida o iSGLT2 <span title="when there are CKM indications">cuando existan indicaciones CKM</span>.

<span title="Main idea">Idea principal</span>: <span title="start with CKM risk and weight goals">comience con los objetivos de riesgo CKM y peso</span>. <span title="Add GLP-1RA or tirzepatide and SGLT2 inhibitor early">Agregue GLP-1RA o tirzepatida e iSGLT2 de forma temprana</span> <span title="to protect organs">para proteger órganos</span>, <span title="not just to control glucose">no solo para controlar la glucosa</span>.

---
DIALOGUE

Narrator: <span title="Today, the doctor talks with a patient">Hoy, el médico habla con un paciente</span> <span title="about new ways to manage diabetes and obesity">sobre nuevas formas de manejar la diabetes y la obesidad</span>.
Physician: <span title="Hello, I want to talk today">Hola, quiero hablar hoy</span> <span title="about your diabetes and your weight">sobre su diabetes y su peso</span>.
Patient: <span title="That's fine, doctor">Está bien, doctor</span>. <span title="My blood sugar is not very high now">Mi azúcar no está muy alta ahora</span>. <span title="Is that good?">¿Eso es bueno?</span>
Physician: <span title="Yes, that's good">Sí, eso es bueno</span>. Pero <span title="we also want to protect">también queremos proteger</span> <span title="your heart and your kidneys">su corazón y sus riñones</span>, <span title="not just lower blood sugar">no solo bajar el azúcar</span>.
Patient: <span title="How can we do that?">¿Cómo podemos hacer eso?</span>
Physician: <span title="We can use new medications">Podemos usar medicamentos nuevos</span>, <span title="such as GLP-1 receptor agonists or tirzepatide">como los agonistas del receptor GLP-1 o la tirzepatida</span>. <span title="They help with weight loss">Ayudan a perder peso</span> y <span title="protect your organs">protegen sus órganos</span>.
Patient: <span title="Will these medications also help my heart?">¿Estos medicamentos también ayudarán a mi corazón?</span>
Physician: <span title="Yes. Some GLP-1 receptor agonists">Sí. Algunos agonistas del receptor GLP-1</span>, <span title="such as semaglutide">como la semaglutida</span>, <span title="also reduce the risk of heart attack and stroke">también reducen el riesgo de infarto y accidente cerebrovascular</span>.
Patient: <span title="I have some kidney problems">Tengo algunos problemas de riñón</span>. <span title="Can I use these medications?">¿Puedo usar estos medicamentos?</span>
Physician: <span title="Yes, and you may also need an SGLT2 inhibitor">Sí, y también puede necesitar un inhibidor de SGLT2</span>. <span title="This medication protects the kidneys">Este medicamento protege los riñones</span> y <span title="helps in heart disease">ayuda en la enfermedad cardíaca</span>, <span title="even if blood sugar is okay">incluso si el azúcar en sangre está bien</span>.
Patient: <span title="Can I take both medications together?">¿Puedo tomar ambos medicamentos juntos?</span>
Physician: <span title="Yes, if you have obesity and kidney or heart problems">Sí, si tiene obesidad y problemas de riñón o corazón</span>, <span title="we can use them together for more protection">podemos usarlos juntos para mayor protección</span>.
Patient: <span title="Do I need to stop taking my metformin?">¿Necesito dejar de tomar mi metformina?</span>
Physician: <span title="No, you can keep taking metformin">No, puede seguir tomando metformina</span>. <span title="These new medications are added">Estos medicamentos nuevos se agregan</span> <span title="to protect you more">para protegerlo más</span>.
Patient: <span title="Thank you, doctor">Gracias, doctor</span>. <span title="I want to try the new plan">Quiero probar el nuevo plan</span>.
Physician: <span title="You're welcome. Let's get started and see how it goes">De nada. Vamos a empezar y ver cómo le va</span>.

    </section>

    <!-- English below -->

    <details open class="card content">
      <summary>INGLÉS</summary>
STORY

Diabetes and obesity are key parts of cardiometabolic (CKM) disease. New ADA guidance says care should focus less on glucose and more on organ protection and weight.

Use GLP-1 receptor agonists or tirzepatide for most patients with type 2 diabetes and obesity when weight loss and CKM risk reduction are main goals. This is true even if baseline HbA1c is not high, when cardiorenal indications are present (for example, semaglutide STEP; tirzepatide SURMOUNT and SURPASS).

For patients with established ASCVD or high risk, pick a GLP-1RA with proven MACE reduction (for example, semaglutide, dulaglutide). Tirzepatide improves weight and metabolic risk factors, but CV outcome data for MACE are still not final.

In heart failure (especially HFpEF) or CKD (eGFR ≥20–25 mL/min/1.73 m², agent-specific), start an SGLT2 inhibitor with outcomes data (empagliflozin, dapagliflozin, canagliflozin) early, at any HbA1c, based on EMPA-REG, DAPA-HF, EMPEROR, CREDENCE, and DAPA-CKD.

For patients with both obesity and CKD or HF, use GLP-1RA or tirzepatide plus SGLT2i together if possible. Early use for weight, HF, renal, and ASCVD risk is more important than order.

Metformin is still fine as first drug. But do not wait to start GLP-1RA, tirzepatide, or SGLT2i when CKM indications are present.

Main idea: begin with CKM risk and weight goals. Add GLP-1RA or tirzepatide and SGLT2i early to protect organs, not only to control glucose.

---
DIALOGUE

Narrator: Today, the doctor talks with a patient about new ways to manage diabetes and obesity.
Physician: Hello, I want to talk about your diabetes and weight today.
Patient: Okay, doctor. My sugar is not very high now. Is that good?
Physician: Yes, that is good. But we also want to protect your heart and kidneys, not just lower sugar.
Patient: How can we do that?
Physician: We can use new medicines, like GLP-1 receptor agonists or tirzepatide. They help with weight loss and protect your organs.
Patient: Will these medicines help my heart too?
Physician: Yes. Some GLP-1 receptor agonists, like semaglutide, also lower heart attack and stroke risk.
Patient: I have some kidney problems. Can I use these medicines?
Physician: Yes, and you may also need an SGLT2 inhibitor. This medicine protects kidneys and helps in heart disease, even if blood sugar is okay.
Patient: Can I take both medicines together?
Physician: Yes, if you have both obesity and kidney or heart problems, we can use them together for more protection.
Patient: Do I need to stop my metformin?
Physician: No, you can still take metformin. These new medicines are added to help protect you more.
Patient: Thank you, doctor. I want to try the new plan.
Physician: You are welcome. Let us start and see how you do.
    </details>
  </main>

  <footer class="subtle">
    <div>© Dec 23, 2025 · Mezra.AI · Practica todos los días.</div>
  </footer>

  <div class="debug">EN: found</div>

  <!-- NEW: light cache-busting helper -->
  <script>
  (function() {
    // 1. Get the version tag from the URL, if present (?v=SHA...)
    var params = new URLSearchParams(window.location.search);
    var version = params.get('v');

    // 2. Read the debug indicator already inside your page
    var debug = document.querySelector('.debug');
    var debugText = debug ? debug.textContent.trim() : '';

    // 3. Heuristic: if version is missing or debug looks suspicious, force a one-time reload
    var isLikelyStale =
      !version ||
      debugText === '' ||
      debugText.indexOf('placeholder') !== -1 ||
      debugText.indexOf('not found') !== -1 ||
      debugText.length < 3;

    if (isLikelyStale) {
      if (!params.get('forceReload')) {
        params.set('forceReload', '1');
        var newUrl = window.location.pathname + '?' + params.toString();
        window.location.replace(newUrl);
      }
    }
  })();
  </script>

  <!-- Existing tooltip behavior -->
  <script>
  (function () {
    document.querySelectorAll('.content').forEach(function(container) {
      container.querySelectorAll('span[title]').forEach(function(span) {
        var text = span.textContent;
        var tip  = span.getAttribute('title');
        var btn  = document.createElement('button');
        btn.className = 'tip-word'; btn.type = 'button';
        btn.textContent = text; btn.setAttribute('data-tip', tip);
        span.replaceWith(btn);
      });
    });

    var openTip = null;
    function closeTip(){ if(openTip){ openTip.remove(); openTip = null; } }
    function showTip(target){
      closeTip();
      var tipText = target.getAttribute('data-tip') || '';
      if(!tipText) return;
      var bubble = document.createElement('div');
      bubble.className = 'tooltip';
      bubble.textContent = tipText;
      document.body.appendChild(bubble);
      var r = target.getBoundingClientRect();
      var m = 8, vw = innerWidth, vh = innerHeight;
      var rect = bubble.getBoundingClientRect();
      var tw = rect.width;
      var th = rect.height;
      var left = r.left, top = r.bottom + m;
      if (left + tw + m > vw) left = Math.max(m, vw - tw - m);
      if (left < m) left = m;
      if (top + th + m > vh) top = Math.max(m, r.top - th - m);
      bubble.style.left = left + 'px';
      bubble.style.top  = top + 'px';
      openTip = bubble;
    }

    document.addEventListener('click', function(e) {
      var word = e.target.closest('.tip-word');
      if (word){ if (openTip) closeTip(); else showTip(word); e.stopPropagation(); }
      else { closeTip(); }
    });
    document.addEventListener('touchstart', function(e) {
      if (!e.target.closest('.tip-word')) closeTip();
    }, { passive: true });
    addEventListener('scroll', closeTip, { passive: true });
    addEventListener('resize', closeTip);
    document.addEventListener('keydown', function(e) { if (e.key === 'Escape') closeTip(); });
  })();
  </script>
</body>
</html>